drugset
drugset / Trial / NCT00268970

Satraplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

NCT00268970 ↗

Phase 2 Completed 40 enrolled Agennix
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC).

Timeline

Start
2005-12
Primary completion
2007-04
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Paclitaxel Small molecule 200 mg/m2 Intravenous
Subject Satraplatin Other / unclassified 60 mg/m2 Oral

Indications

non-small cell lung carcinoma